Ascendis Pharma vs Jazz Pharmaceuticals

Ascendis Pharma (ASND), health care, and Jazz Pharmaceuticals (JAZZ), health care, side by side on market value, valuation, margins, balance sheet and price change. Higher and lower are marked; neither is called better.

Ascendis Pharma is worth $17.8B on the stock market and Jazz Pharmaceuticals $15.5B: Ascendis Pharma is valued at 15% more. Ascendis Pharma trades at 17.8 times earnings and Jazz Pharmaceuticals at 71.2; operating margins in their latest fiscal years were -18.9% and -10.1%. Over the past year Ascendis Pharma's share price has moved +25.1% and Jazz Pharmaceuticals's +32.8%.

Key facts

Ascendis Pharma market value
$17.8B
Jazz Pharmaceuticals market value
$15.5B
Ascendis Pharma P/E
17.8
Jazz Pharmaceuticals P/E
71.2
Ascendis Pharma revenue
$799MFY to 2025-12-31
Jazz Pharmaceuticals revenue
$4.3BFY to 2025-12-31
Superinvestors holding both
0

Market values as of .

Ascendis Pharma vs Jazz Pharmaceuticals: every measure side by side
Measure Ascendis Pharma Jazz Pharmaceuticals
SectorHealth CareHealth Care
Country Denmark Ireland
Fiscal year ends2025-12-312025-12-31
Size
Market cap$17.8Bhigher$15.5Blower
Revenue$799Mlower$4.3Bhigher
Earnings-$253Mhigher-$356.1Mlower
Employees1,189lower2,890higher
Total assets$1.4Blower$11.7Bhigher
Valuation
P/E17.8lower71.2higher
P/S22.3higher3.6lower
P/B——
Dividend yield——
Profitability
Operating margin-18.9%lower-10.1%higher
Balance sheet
Net assets-$180.7Mlower$4.3Bhigher
Total liabilities$1.6Blower$7.3Bhigher
Total debt$799.1Mlower$5.4Bhigher
Cash on hand$683.5Mlower$1.4Bhigher
Price change
Today-0.20%lower+0.39%higher
1 year+25.1%lower+32.8%higher

Market value, P/E, P/B, dividend yield and price changes are from live quotes (Yahoo Finance; prices may be delayed 15 minutes or more). Revenue, earnings, operating margin and the balance-sheet figures are from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day. P/S sets today's market value against the latest fiscal year's revenue. “Higher” and “lower” compare the two numbers only; a higher P/E or more debt is not better. Dividend yield and P/B are shown only for companies based in the US. A dash means no figure is on file.

Loading the one-year price chart…

Which superinvestors hold them

From each tracked investor's latest 13F filing. A 13F lists long positions in US-listed shares at a quarter end, filed up to 45 days later.

Both (0)

None of the tracked investors.

Ascendis Pharma only (2)

Percentages are each holding's share of that investor's reported portfolio. Who owns ASND · Who owns JAZZ

Further comparisons

Learn

Questions and answers

Which is bigger, Ascendis Pharma or Jazz Pharmaceuticals?

By market value, Ascendis Pharma is the larger: $17.8B against $15.5B for Jazz Pharmaceuticals. By revenue in its latest fiscal year, Jazz Pharmaceuticals is the larger: $4.3B against $799M for Ascendis Pharma.

Which has the higher P/E ratio?

Jazz Pharmaceuticals: 71.2, against 17.8 for Ascendis Pharma. A higher P/E means the market pays more for each dollar of the last twelve months' earnings; on its own it does not say which is the better value.

Which has the higher operating margin?

Jazz Pharmaceuticals: -10.1%, against -18.9% for Ascendis Pharma. Operating margin is operating income as a share of revenue in the latest fiscal year.

Which has more debt?

Jazz Pharmaceuticals: $5.4B, against $799.1M for Ascendis Pharma. Total debt is borrowings at the end of the latest fiscal year, as each company reported it; it is not set against cash here.

Which superinvestors own both Ascendis Pharma and Jazz Pharmaceuticals?

None of the tracked superinvestors holds both in their latest 13F filing. 2 hold Ascendis Pharma and 5 hold Jazz Pharmaceuticals.

Cite this page

Funkfolio, “Ascendis Pharma vs Jazz Pharmaceuticals”, data as of 17 November 2026. https://funkfolio.com/compare/asnd-vs-jazz

Underlying data: Yahoo Finance quotes; SEC annual reports collected 2026-11-12; 13F filings.